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Abstract
Introduction:  Mucopolysaccharidosis  (MPS)  is  a  lysosomal  storage  disease  caused  by  deﬁciency
of -l-iduronidase.  The  otolaryngological  ﬁndings  include  hearing  loss,  otorrhea,  recurrent  oti-
tis, hypertrophy  of  tonsils  and  adenoid,  recurrent  rhinosinusitis,  speech  disorders,  snoring,  oral
breathing  and  nasal  obstruction.
Objective:  To  evaluate  the  impact  of  enzymatic  replacement  therapy  with  laronidase
(Aldurazyme®)  in  patients  with  mucopolysaccharidosis  (MPS  I),  regarding  sleep  and  hearing
disorders,  and  clinical  manifestations  in  the  upper  respiratory  tract  (URT).
Methods:  Nine  patients  with  MPS  I (8  Hurler-Scheie,  and  1  Scheie  phenotypes)  of  both  sexes,
ages ranging  between  3  and  20  years,  were  included  in  this  study.  Patients  were  evaluated
between  seven  and  11  months  before  the  treatment  and  between  16  and  22  months  after  the
onset of  the  enzymatic  replacement.  They  were  all  submitted  to  a  clinical  and  otolaryngological
evaluation,  including  nasoﬁbroscopical,  polysomnographic  and  audiologic  exams.
Results: The  results’  data  showed  decreasing  of  the  frequency  of  ear,  nose  and  throat  infec-
tions, with  improvement  of  the  rhinorrhea  and  respiratory  quality.  No  remarkable  changes
were observed  regarding  macroglossia  and  tonsil  and  adenoid  hypertrophy.  Audiometric  and
polysomnographic  evaluations  did  not  show  statistical  signiﬁcance.
 Please cite this article as: Dualibi AP, Martins AM, Moreira GA, de Azevedo MF, Fujita RR, Pignatari SS. The impact of laronidase treatment
n otolaryngological manifestations of patients with mucopolysaccharidosis. Braz J Otorhinolaryngol. 2016;82:522--8.
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Conclusion:  Enzymatic  replacement  therapy  in  patients  with  mucopolysaccharidosis  I  provides
control of  recurrent  URT  infections,  rhinorrhea  and  respiratory  quality,  however  it  is  does  not
seem to  improve  audiologic  and  polisomnographic  parameters,  with  no  effect  on  adenoid  and
tonsils hypertrophy  and  macroglossia.
© 2015  Associac¸a˜o  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Ce´rvico-Facial.  Published
by Elsevier  Editora  Ltda.  This  is  an  open  access  article  under  the  CC  BY  license  (http://
creativecommons.org/licenses/by/4.0/).
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Impacto  do  tratamento  com  laronidase  nas  manifestac¸ões  otorrinolaringológicas
de  pacientes  com  mucopolissacaridose
Resumo
Introduc¸ão:  Mucopolissacaridose  (MPS)  é  uma  doenc¸a  de  depósito  lisossômico  causada  pela
deﬁciência  de  -l-iduronidase.  Os  achados  otorrinolaringológicos  incluem  perda  auditiva,  otor-
reia, otites  de  repetic¸ão,  hipertroﬁa  adenotonsilar,  rinossinusite  recorrente,  distúrbios  da  fala,
roncos, respirac¸ão  bucal  e  obstruc¸ão  nasal.
Objetivo:  Avaliar  o  impacto  da  terapia  de  reposic¸ão  enzimática  com  laronidase  (Aldurazyme®)
em pacientes  com  mucopolissacaridose  I (MPS  I)  em  relac¸ão  ao  sono,  distúrbios  auditivos  e
manifestac¸ões clínicas  do  trato  respiratório  superior  (TRS).
Método:  Nove  pacientes  com  MPS  I  (oito  com  fenótipo  Hurler-Scheie  e  um  com  fenótipo  Scheie),
de ambos  os  sexos,  com  idades  variando  entre  3  e  20  anos,  foram  incluídos  neste  estudo.  Os
pacientes foram  avaliados  entre  7  e  11  meses  antes  do  tratamento  e  entre  16  e  22  meses
após o  início  da  reposic¸ão  enzimática.  Todos  foram  submetidos  a  uma  avaliac¸ão  clínica  e
otorrinolaringológica,  incluindo  nasoﬁbroscopia,  polissonograﬁa  e  exames  radiológicos.
Resultados:  Os  dados  dos  resultados  mostraram  diminuic¸ão  da  frequência  de  infecc¸ões  de
orelha, nariz  e  garganta,  com  melhora  da  rinorreia  e  da  qualidade  respiratória.  Mudanc¸as
signiﬁcativas  não  foram  observadas  em  relac¸ão  à  macroglossia  e  à  hipertroﬁa  adenotonsilar.
Avaliac¸ões audiométricas  e  polissonográﬁcas  não  apresentaram  signiﬁcância  estatística.
Conclusão:  A  terapia  de  reposic¸ão  enzimática  em  pacientes  com  mucopolissacaridose  I  fornece
controle de  infecc¸ões  recorrentes  do  TRS,  rinorreia  e  qualidade  respiratória,  porém,  não  parece
melhorar  os  parâmetros  audiológicos  e  polissonográﬁcos,  ou  exercer  efeito  sobre  a  hipertroﬁa
adenotonsilar  e  macroglossia.
©  2015  Associac¸a˜o  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Ce´rvico-Facial.  Publicado
por Elsevier  Editora  Ltda.  Este e´  um  artigo  Open  Access  sob  uma  licenc¸a  CC  BY  (http://
creativecommons.org/licenses/by/4.0/).
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Mucopolysaccharidosis  (MPS)  is  a  lysosomal  storage  disease
caused  by  deﬁciency  of  an  enzyme  involved  in  the  degra-
dation  of  glycosaminoglycans  (GAGs).  They  are  classiﬁed
according  to  the  involved  enzyme  and  GAG  in  seven  types:
I  (Hurler,  Hurler  Scheie  and  Scheie),  II  (Hunter),  III  (San-
ﬁllipo),  IV  (Morquio),  VI  (Maroteaux  Lamy),  VII  (Sly)  e  IX
(Natowicz).1--3
MPS  I  is  caused  by  deﬁciency  of  -l-iduronidase,  which
leads  to  intralysosomal  deposits  of  dermatan  and  heparan
sulfate.  It  is  an  autosomic  recessive  genetic  disease,  with
estimated  incidence  varying  from  1:100,000  for  severe  cases
to  1:800,000  for  cases  with  mild  manifestations.4
Clinical  manifestations  of  MPS  I  are  extremely  het-
erogeneous,  with  symptoms  that  evolve  in  many  ways,
from  very  mild  manifestations  of  late  development,  with-
out  cognitive  disorders,  and  high  life  time  expectation
(Scheie),  to  very  severe  cases  of  early  onset,  rapidly  pro-
gressive,  with  neural  degeneration  and  limited  capabilities
u
t
sn  life,  usually  manifested  by  the  ﬁrst  decade  (Hurler),
nd  passing  through  an  intermediary  level  of  severity
Hurler--Scheie).1,2,5
The  disease  may  involve  nervous,  skeleton,  digestive,
ardiac,  superior  and  inferior  respiratory  systems  presenting
ifferent  levels  of  severity  in  an  independent  manner.
egarding  the  otolaryngological  ﬁndings,  the  most  frequent
ymptoms  include  hearing  loss,  otorrhea,  recurrent  otitis,
ypertrophy  of  tonsils  and  adenoid,  recurrent  rhinosinusi-
is,  speech  disorders,  snoring,  oral  breathing  and  nasal
bstruction.1,2,6
Obstructive  sleep  apnea  and  hypopnea  syndrome  (OSAHS)
s  frequently  diagnosed  in  MPS  I  patients.  Obstructive  and
estrictive  factors  such  as  reduction  of  the  thoracic  volume
musculoskeletal  alterations),  restriction  of  the  diaphrag-
atic  movement  due  to  hepatosplenomegaly,  presence  of
telectasis  secondary  to  the  reduction  of  the  lung  vol-
me,  deposit  of  GAGs  into  the  pulmonary  interstitial  tissue,
racheal  stenosis,  vocal  cord  thickening,  adenoid  and  ton-
il  hypertrophy,  macroglossia,  short  neck,  thickened  high
5p
m
f
m
l
h
e
a
o
z
m
a
t
a
t
c
p
a
i
r
b
o
s
t
2
T
c
t
a
o
c
m
o
a
c
s
s
A
q
s
l
c
l
p
r
M
N
a
(
0
e
a
b
o
a
c
(
b
>
i
t
A
t
<
a
(
n
m
R
F
f
w
w
2
g
g
s
i
a
l
t
b
i
a
n
m
p
a
t
n
s
s
t
m
t24  
ositioned  epiglottis,  presence  of  abundant  thick  nasal
ucous,  and  limited  mouth  opening  are  mainly  responsible
or  the  respiratory  disorders.6--11 Hearing  loss  is  also  com-
on  in  patients  with  MPS  I.  Although  the  nature  of  hearing
oss  may  be  conductive,  sensorineural  or  mixed,  conductive
earing  loss  is  more  frequent  and  can  be  explained  by  sev-
ral  factors,  such  as  the  thickening  of  the  middle  ear  mucus
nd  eardrum  produced  by  deposits  of  GAGs,  Eustachian  tube
bstruction,  ossicular  chain  malformation,  hypopneumati-
ation  of  the  temporal  bone  and  presence  of  thick  copious
ucus.  Mechanisms  to  explain  the  sensorineural  hearing  loss
re  unclear.  It  is  believed  that  a  progressive  hyperplasia  of
he  arachnoid  membrane  can  compress  the  cochlear  nerve,
nd  that  the  storage  of  GAGs  inside  neurovascular  struc-
ures  of  the  inner  ear,  along  with  alterations  of  the  hairy
ells  consequent  to  metabolic  disorders  usually  present  in
atients  with  MPS,  may  be  contributory  factors.2,9,12--17
Due  to  the  multisystem  involvement,  treatment  is  usu-
lly  multidisciplinary.  Until  the  1970s,  treatment  consisted
n  palliative  methods  to  improve  the  quality  of  life.  Cur-
ently,  the  two  principal  therapeutic  tools  of  MPS  I are
ased  on  enzymatic  replacement  (ERT)  and  transplantation
f  hematopoietic  cells  (HCT).  The  enzymes  produced  by
tem  cells  from  bone  marrow  or  umbilical  cord  restore  to
he  patient  the  ability  of  degradation.  Since  1981,  more  than
00  children  have  been  submitted  to  this  type  of  treatment.
he  HCT  produces  resolution  or  improvement  of  OSAHS  and
onductive  hearing  loss.  The  major  problem  related  to  this
reatment  is  the  high  rate  of  morbidity  and  mortality  (40%),
nd  the  difﬁculty  to  ﬁnd  compatible  bone  marrow.  Because
f  the  high  risk  related  to  this  therapy,  it  is  restricted  to
hildren  with  severe  disease,  preferable  before  the  18th
onth  of  life,  when  the  CNS  alterations  usually  begin  to
ccur.18--21
Laronidase  (Aldurazyme®)  is  the  enzyme  used  in  MPS  I,
nd  it  is  produced  by  recombinant  DNA  technique.  Clini-
al  trials  with  ERT  have  shown  improving  of  the  respiratory
tatus.  It  was  approved  by  commercial  use  in  2003,  and
ince  then  more  than  330  patients  have  been  treated.22--26
lthough  improvement  of  the  respiratory  conditions  is  fre-
uently  mentioned  in  the  majority  of  the  reports,  few
tudies  have  addressed  the  hearing  problems  and  other  oto-
aryngological  ﬁndings  that  remain  unclear.27,28
The  individuals  included  in  this  study  are  part  of  the  ﬁrst
linical  trial  of  treatment  of  MPS  I  with  laronidase  in  Brazil.
The  objective  was  to  evaluate  the  impact  of  ERT  with
aronidase  in  respiratory  and  audiological  manifestations  of
atients  with  MPS  I  and  clinical  manifestations  in  the  upper
espiratory  tract  (URT).
ethod
ine  patients  with  MPS  I  (no-Hurler  phenotype)  were  evalu-
ted  after  approval  of  the  Committee  of  Ethics  in  Research
protocol  0337/05).
Each  patient  received  52  infusions  of  laronidase,
.54  mg/kg/dose.
They  were  all  submitted  to  at  least  two  otolaryngological
valuations,  including  nasoﬁbroscopic,  polysomnographic
nd  audiological  examination,  between  seven  and  11  months
t
i
bDualibi  AP  et  al.
efore  and  between  16  and  22  months  after  the  beginning
f  the  treatment.
Tonsils  3  and  4  according  to  Brodsky  classiﬁcation,  and
denoids  occupying  more  than  70%  of  the  choanae  were
onsidered  hypertrophic.29
The  data  obtained  from  polysomnographic  examination
PSG)  were  analyzed  according  to  the  parameters  deﬁned
y  the  American  Thoracic  Society  (index  of  apnea  hipopnea
1  event/h  in  children  under  14  years  of  age  and  >5  events/h
n  older  children).30,31
Audiological  evaluation  was  accomplished  by  conven-
ional  audiometric  exam  alone  or  with  visual  reinforcement.
nalysis  of  the  data  was  based  on  SRT  (‘‘speech  reception
hreshold’’).  It  was  considered  normal  when  the  SRT  was
 or  equal  20  (dB).  Imitanciometric  curve  was  interpreted
ccording  to  Jerger  classiﬁcation  (1970).32,33
Statistical  evaluation  was  analyzed  by  the  Friedman  test
non-parametric).  The  value  of  rejection  for  hypothesis  of
ullity  was  ﬁxed  for  values  <  or  equal  0.05.  Signiﬁcance  was
arked  as  (*).  Non-signiﬁcant  (NS).
esults
rom  the  nine  patients  initially  evaluated,  two  did  not  return
or  the  second  visit  after  the  beginning  of  treatment  and
ere  not  included  in  the  statistical  analysis.  Four  patients
ere  female  and  ﬁve  male,  and  ages  ranged  between  3  and
0  years  (median  of  8  years).
One  patient  did  not  have  a  pre-treatment  polysomno-
raphic  exam  and  was  not  included  in  the  ﬁnal  polysomno-
raphic  evaluation.
Three  patients  had  undergone  ENT  surgery  before  the
tart  of  this  study:  in  addition  to  myringotomy  with  ventilat-
ng  tube  placement,  one  patient  underwent  adenoidectomy
t  the  age  of  7,  one  patient  was  referred  to  adenotonsil-
ectomy  at  the  age  of  4  and  another  patient  held  elective
racheotomy  and  adenoidectomy  at  4  years  of  age.
Fig.  1  shows  that  nasal  obstruction,  snoring,  oral
reathing,  apnea,  rhinorrhea,  and  recurrent  URT  infections
mproved  with  ERT  in  practically  all  patients.
Otolaryngological  examination  showed  that  macroglossia
nd  appearance  of  the  tympanic  membrane  (retraction)  did
ot  change  after  ERT.  In  the  three  patients  without  tympanic
embrane  retraction,  two  had  patent  ventilating  tubes  in
lace.  All  patients  experienced  reduction  of  nasal  mucus
fter  ERT  (Fig.  2).
Naso-ﬁberscopic  examination  also  showed  reduction  of
he  nasal  secretion,  however,  reduction  of  tonsil  size  was
ot  observed  (Fig.  3).
The  results  obtained  by  audiometric  evaluation  are
hown  in  Table  1.  Statistical  analysis  did  not  demonstrate
igniﬁcance  of  the  differences  between  pre-  and  post-ERT.
Tympanometry  was  performed  in  only  ﬁve  patients,  since
wo  had  bilateral  patent  ventilating  tubes  in  place  at  the
oment  of  the  evaluation.  In  the  ﬁrst  evaluation  four  of
hem  presented  B-type  curve  and  one  patient  presented  A-
ype  curve,  remaining  unchanged  after  ERT.
Results  obtained  with  polysomnographic  exams  are  shown
n  Table  2. Statistical  analysis  did  not  show  signiﬁcance
etween  the  parameters  pre-  and  post-therapy.
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Figure  1  Otolaryngological  symptoms  obtained  from  directed  anamnesis.
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DiscussionSince  the  ﬁrst  description  of  MPS,  at  the  beginning  of  the
20th  century,  the  knowledge  of  this  progressive  disease  of
large  phenotypic  diversity,  as  well  as  signiﬁcant  limitation
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Figure  3  Major  ﬁndings  at  the  nlogical  ﬁndings.
f  quality  and  expectancy  of  life  have  expanded  consider-
bly.  However,  despite  the  remarkable  improvement  of  the
nderstanding  of  its  natural  history  and  treatment,  many
uestions  remain  unsolved.  There  is  a  lack  of  information
egarding  the  evolution  of  non-treated  patients,  and  the
s
First evaluation pre treatment
Second evaluation pre treatment
Post treatment evaluation
aso-ﬁberoscopy  examination.
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Table  1  Results  of  STR  (dB).
Patients  1st  evaluation
pre  treatment
2nd  evaluation
pre  treatment
3rd  evaluation
post  treatment
RE  LE  RE  LE  RE  LE
1  30  35  15  20  20  15
2 20  20  25  25  20  30
3 50  60  50  60  65  55
4 55  50  60  35  55  35
5 80  60  90  95  75  80
6 45  50  75  70  80  70
7 75  75  60  60  55  70
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arity  and  large  phenotypic  heterogenicity  of  MPS  I  make
he  development  of  a  study  of  clinical  relevance  difﬁcult,
articularly  due  to  the  diversity  of  clinical  presentations.
he  absence  of  speciﬁc  scores  and  biomarkers  represents
n  additional  problem  to  monitor  the  efﬁcacy  of  any  kind  of
herapeutic  protocol.4
Most  of  the  studies  enrolling  patients  with  MPS  I  and  ERT
ave  addressed  more  advanced  stages  of  the  disease.  The
resent  study  is  prospective,  observational  longitudinal,  and
he  patients  were  already  presenting  established  lesions.
his  may  have  contributed  to  the  low  expressive  results.
Otolaryngological  complaints  (oral  breathing,  snoring,
earing  loss,  nasal  obstruction,  rhinorrhea,  recurrent  URT
nfections)  and  clinical  ﬁndings  (macroglossia,  hypertrophy
f  tonsils  and  adenoid,  nasal  secretion  and  retraction  of  tym-
anic  membrane)  are  frequently  reported  in  the  medical
iterature.8--12
In  our  study,  we  observed  a  decrease  in  frequency  of  prac-
ically  all  otolaryngologic  complains  after  ERT,  with  marked
eduction  in  rhinorrhea  and  URT  recurrent  infections.  We
elieve  that  the  reduction  of  the  GAG  deposits  in  the  middle
ar  and  URT,  and  consequent  improvement  of  the  nasal  ﬂow
nd  Eustachian  tube  could  have  been  the  reason  for  such
mprovement.  Interestingly,  hypoacusia  frequency  increased
fter  ERT.Most  of  our  results  are  similar  to  those  reported  in
he  literature.  In  phase  I/II  clinical  trials,  authors  have
eported  90%  of  the  patients  presenting  with  recurrent  URT
e
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m
Table  2  Apnea--hypopnea  indexes  (IAH)  and  time  of  sleep  with  o
Patients  IAH  
1st  2nd  3rd
1  10.9  12.3  12.
2 11.2  1.3  39.
3 0.3  0  0.
4 48.1  54.5  60.
5 9.3  14  10.
6 17.6  15.4  14.
Friedman’s test.
IAH, 2 calc = 1.826; N.S., p = 0.401.
Time of sleep with oxygen sat <90%, 2 calc = 0.087; N.S., p = 0.957.nfections,  and  improvement  after  ERT.23 Sardón  et  al.
escribed  two  patients  under  ERT,  with  signiﬁcant  reduction
f  the  tracheotomy  secretions  in  one  of  the  patients  after
0  weeks  of  laronidase,  although  no  improvement  of  the
ypoacusia  could  be  observed.28 Tokic  et  al.,  in  2007,
eported  two  cases  of  MPS  I  submitted  to  ERT,  with
emarkable  improvement  of  the  URT  recurrent  infections
n  both  patients,  and  also  improvement  of  the  audiological
arameters.29
Along  the  time,  naso-ﬁberoptic  examination  showed  con-
inuous  increase  of  hypertrophy  of  tonsils  and  adenoids,  as
uch  as  nasal  secretions,  in  evaluations  before  ERT.  After
he  beginning  of  ERT,  nasal  secretion  showed  important
eduction,  but  no  changes  regarding  tonsils’  hypertrophy
ere  observed.  There  are  no  references  in  the  literature
egarding  the  volume  of  the  tonsils  and  adenoids  in  MPS
 patients  submitted  to  ERT.  However,  some  authors  per-
ormed  tonsillectomy  and  adenoidectomy  in  at  least  ﬁve
atients  undergoing  ERT,  and  this  fact  may  reﬂect  the
bsence  of  improvement  of  this  clinical  parameter.27
Regarding  the  hearing  loss,  there  is  a  consensus  among
he  reports  that  MPS  I  patients  present  with  hypoacusia,  and
lthough  some  authors  report  improvement  after  HCT,  few
ave  evaluated  the  evolution  of  dysacusia  after  ERT.  Sardón
t  al.,  in  2005,  evaluated  two  patients  performing  brain
voked  response  audiometry  (BERA),  detecting  conductive
earing  loss  in  one.  The  patient  did  not  present  improve-
ent  after  ERT.23 Tokic  et  al.,  in  2007,  also  evaluated  two
xygen  saturation  inferior  to  90%.
T  sat  <  90%
 1st  2nd  3rd
3  2.7  12.5  12.5
3  2  0  7
4  10  20  32
6  100  91  94
6  3.4  7  2
1  2.3  0.2  0
nifes
r
c
i
O
e
i
o
e
a
s
m
q
a
t
e
c
t
s
o
o
r
C
A
o
l
r
s
c
p
n
C
T
RThe  impact  of  laronidase  treatment  in  otolaryngological  ma
patients  hearing  by  using  traditional  audiometry.  A  mixed
conductive-sensorineural  hearing  loss  was  observed  in  one
patient,  with  no  changes  after  ERT,  and  conductive  hearing
loss  was  observed  in  the  other,  which  presented  improve-
ment  of  the  thresholds  from  30  dB  to  10  dB  in  one  ear  and
90  dB  to  60  dB  in  the  other  ear  after  ERT.29
One  hundred  percent  of  our  patients  presented  hearing
loss  of  varying  levels.  Two  patients  had  ventilation  tubes
in  place  and  were  not  submitted  to  tympanometry.  Type-B
curve  was  observed  in  80%  of  the  remaining  ﬁve  patients.
There  was  no  statistical  signiﬁcance  of  the  values  between
just  before  and  after  ERT,  however,  according  to  the  medi-
ans,  it  was  possible  to  verify  that  the  hearing  loss  was  getting
worse  before  ERT,  and  had  a  slight  increase  after  treatment.
Along  with  the  improvement  of  the  URT  infections  and  rhin-
orrhea,  a  better  result  regarding  the  hearing  thresholds  was
also  expected,  but  possibly  other  factors  such  as  ossicular
chain  malformation,  thickening  of  the  middle  ear  mucosa,
and  Eustachian  tube  dysfunction  were  responsible  for  the
maintenance  of  the  audiological  status.  On  the  other  hand,
sensorineural  hearing  losses  are  usually  progressive  and  tend
to  worsen  the  audiologic  threshold  of  MPS  I patients,  even
during  ERT,  since  the  enzyme  does  not  cross  the  hematoen-
cephalic  barrier.17
When  ﬁrst  submitted  to  polysomnographic  examination,
all  patients  presented  OSAHS,  except  one  patient  who  had
had  tracheostomy  before  the  beginning  of  the  study,  and  no
OSAHS  was  registered  in  any  occasion.  Overall,  the  results
did  not  show  statistical  difference  between  the  pre-  and
post-ERT  measurements,  however,  based  on  the  medians,  we
observed  that  the  polysomnographic  parameters  were  dete-
riorating  before  therapy  and  presented  stabilization  after
the  ERT.  This  phenomenon  was  also  observed  for  the  medians
of  the  time  of  oxyhemoglobin  under  90%.
According  to  the  literature  most  of  the  patients  improved
their  respiratory  status  after  ERT.  Phases  I/II  clinical  tri-
als  have  shown  that  all  patients  with  OSAHS  presented
reduction  of  the  IAH  after  52  weeks  of  ERT  (mean  of
2.1--1  event/h);  two  patients  had  reduction  of  sleep  time
with  oxygen  saturation  under  90%;  one  patient  had  improve-
ment  in  sleep  time.  After  six  years  of  follow-up,  ﬁve  out  of
six  patients  were  re-evaluated,  four  presented  improvement
or  stabilization  of  the  respiratory  status,  and  one  patient
was  worse.26
Phase  III  study  also  showed  reduction  of  the  IAH  in
patients  treated  with  enzyme  when  compared  to  a  placebo
group  (reduction  of  6  events/h  in  the  treated  group,  increase
of  0.3  event/h  in  the  placebo  group).  In  a  study  addressing
children  under  the  age  of  5  years,  reduction  of  8.5%  of  the
IAH  was  observed.  However,  among  six  patients  who  pre-
sented  normal  IAH  before  treatment,  four  remained  normal
and  two  got  worse  after  therapy.25 Tokic  et  al.  also  reported
normalization  to  the  IAH  in  two  patients  after  12  weeks
of  treatment,  along  with  improvement  of  the  respiratory
pattern.29
Few  isolated  reports,  however,  present  contrary  results
regarding  the  respiratory  quality.  Sardón  et  al.  had  a  patient
with  tracheotomy  who  did  not  show  improvement  of  the
respiratory  quality  after  ERT.23 Thomas  et  al.  described
a  severely  diseased  patient  treated  with  ERT  for  three
years  with  no  changes  on  the  progression  of  the  obstructive
picture.34tations  of  patients  with  mucopolysaccharidosis  527
Due  to  the  progressive  pattern  of  MPS  I,  stabilization  or
eduction  of  lesions  and  speed  of  the  disease  progression  are
onsidered  as  beneﬁts  from  the  therapy.2,26
When  a  questionnaire  is  completed  by  the  patients,  stud-
es  have  shown  improvement  in  daily  activities  performance.
ur  patients  have  also  described  a  general  improvement,
ven  regarding  the  hypoacusia,  sleep  and  respiratory  qual-
ty,  which  we  could  not  demonstrate  through  the  results
f  the  objective  exams  (audiometric  and  polysomnographic
valuations).
Current  challenges  for  ERT,  besides  the  development  of
n  early  diagnostic  protocol  (neonatal  screening  test),  con-
ist  of  prediction  of  the  severity  of  the  disease,  in  order  to
ake  an  adequate  choice  of  treatment,  to  develop  an  ade-
uate  treatment  for  the  neuropathies,  and  to  ﬁnd  ways  for
n  effective  monitoring,  with  speciﬁc  instruments  to  quan-
ify  the  improvement  of  life  quality  as  well  as  efﬁcacy  and
ffectiveness  of  the  employed  therapy.  Longer  follow-ups
an  also  contribute  to  the  knowledge  of  the  side  effects  of
he  ERT  as  much  as  the  evaluation  of  the  evolution  of  each
ystem  in  order  to  plan  associated  treatment  programs.2,35,36
Although  this  was  a  study  project  of  a  small  sampling,
verall  there  was  a  remarkable  improvement  of  the  quality
f  life  of  patients  and  a  high  level  of  satisfaction  by  the
elatives  and  health  care  professionals  produced  by  the  ERT.
onclusion
ccording  to  the  results  obtained  from  this  study,  we
bserved  that  MPS  I  patients  submitted  to  ERT  with
aronidase  (Aldurazyme®)  present  improvement  of  the  URT
ecurrent  infections,  rhinorrhea,  and  general  respiratory
tatus,  without  however  presenting  expressive  and  signiﬁ-
ant  improvement  of  the  hearing  loss,  tympanometric  curve
attern,  sleep  disorders,  macroglossia  and  tonsils  and  ade-
oid  hypertrophy.
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